Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative adva...
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
About this item
Full title
Author / Creator
Battisti, Nicolò Matteo Luca , Kingston, Belinda , King, Judy , Denton, Arshi , Waters, Simon , Sita-Lumsden, Ailsa , Rehman, Farah , Stavraka, Chara , Kristeleit, Hartmut , Sawyer, Elinor , Houghton, David , Davidson, Neville , Howell, Sacha , Choy, Julia , Harper, Peter , Roylance, Rebecca , Fharat, Raja , Mohammed, Kabir , Ring, Alistair and Johnston, Stephen
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Purpose
Palbociclib is approved in 1st line for hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC). A Compassionate Access Programme previously allowed patients to receive it in 4th line. However, Palbociclib has not been specifically tested in this population. We aimed to determine the safety and efficacy profile of Palbo...
Alternative Titles
Full title
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
Authors, Artists and Contributors
Author / Creator
Kingston, Belinda
King, Judy
Denton, Arshi
Waters, Simon
Sita-Lumsden, Ailsa
Rehman, Farah
Stavraka, Chara
Kristeleit, Hartmut
Sawyer, Elinor
Houghton, David
Davidson, Neville
Howell, Sacha
Choy, Julia
Harper, Peter
Roylance, Rebecca
Fharat, Raja
Mohammed, Kabir
Ring, Alistair
Johnston, Stephen
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2168010500
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2168010500
Other Identifiers
ISSN
0167-6806
E-ISSN
1573-7217
DOI
10.1007/s10549-019-05134-x
